Using network pharmacology, we identified 7 core targets of curcumol against COVID-19 and COAD, including GABRD, GABRP, BCHE, CYP3A4, PGR, HSD17B2, and SLC6A3. The gene discussed is SLC6A3; the disease is colon adenocarcinoma.